Mr. Doug Drysdale reports

CYBIN ANNOUNCES GRANT OF U.S. PATENT COVERING DEUTERATED TRYPTAMINES

The United States Patent and Trademark Office (USPTO) has granted Cybin Inc. U.S. patent 11,746,088, covering composition of matter for deuterated tryptamine compounds and pharmaceutical compositions thereof, with exclusivity until 2041. The newly granted U.S. patent covers deuterated 5-methoxy-dimethyltryptamine analogues in the company's preclinical deuterated tryptamine portfolio and further strengthens the company's leadership position in the development of potential best-in-class deuterated tryptamine-based therapeutics for the treatment of mental health conditions.

"The grant of this patent is timely as we recently entered into a definitive agreement to acquire Small Pharma Inc., a leading developer of short-duration psychedelic therapeutics, together creating the psychedelic sector's most impressive and robust intellectual property portfolio. The strong synergy of our collective intellectual property provides an unparalleled opportunity to develop novel, differentiated therapeutics for patients in need of improved treatment options," said Doug Drysdale, chief executive officer of Cybin. "Looking towards the next chapter for the combined company, this new composition of matter patent will have an important role in protecting the continued advancement of our development pipeline."

Coming milestones:

• Phase 1 deuterated dimethyltryptamine (dDMT) data in Q3/Q4 2023 are expected to guide the formulation and administration routes in support of a phase 2 efficacy study of dDMT in early 2024;
• Phase 2 top-line efficacy data for CYB003 in major depressive disorder (MDD) and top-line phase 1 data from the CYB004-E study expected in Q3/Q4 2023;
• U.S. Food and Drug Administration (FDA) submission of CYB003 phase 1/2 data for pivotal studies expected following top-line efficacy data readout;
• Preparations under way to support scaling to a potential phase 3 study of CYB003 in early 2024.

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin's goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analogue for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds.

We seek Safe Harbor.